Ephedrine Hydrochloride

Producers shown on SFDA

(Record date:29/09/2021）

Producers shown on EP

(Quoted from EP website；record date:29/09/2021）

Staff size:300-399 persons

Registered capital:RMB 90.964 million

Producer:Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. is subordinate to Apeloa Pharmaceutical Co., Ltd. Apeloa Pharmaceutical Co., Ltd. is a state-level key high-tech enterprise and key enterprise in pharmaceutical industry in Zhejiang Province  .The company is engaged in the research and development, production and sales of pharmaceutical products. The main business is in crude drug (API), contract R & D, production service (CDMO) and preparation (FDF) business. 

 In order to improve market competition, our company build core competitiveness continuesly in quality, EHS and technology . Five of the API plants were certified by GMP, four by FDA, three by PMDA, three by CE in EU, one by WHO, one by KFDA, one by Germany GMP, and all of preparation factory were certified by GMP. In addition to the safety and occupational health management system certification, API plants continue to be audited by EHS audits from international pharmaceutical companies or third parties.

Staff size:1000-1999 persons

Registered capital:RMB 83.75 million

Producer:Chifeng Aike Pharmaceutical Technology Co., Ltd. (hereinafter referred to as our company), established in March 2000, is a manufacturer of various APIs and chemical intermediates, a ephedrine manufacturer designated by the State Food and drug administration, and a national high-tech enterprise. At present, it is a member enterprise of Shanghai Pharmaceutical Group Co., Ltd.

The company's products are exported at home and abroad, and its export business covers Europe, Asia, America and other places. The domestic business covers all provinces except Tibet, and the domestic market share of the products is nearly 50%. The company has successively passed the quality audit of international famous pharmaceutical enterprises such as Sino US Stryker, Wyeth Baigong pharmaceutical, Shanghai Squibb and Shanghai Johnson & Johnson pharmaceutical, and has become their stable supplier.

Staff size:200-299 persons

Registered capital:RMB 40.9 million

Producer:China National Pharmaceutical Industry Corporation Ltd., established in 1991, is subordinate to China Pharmaceutical Group Co., Ltd. With a total area of about 100000 square meters, it has an annual production capacity of nearly 60 tons of API, 5 billion tablets of solid oral preparations, 23 million small volume injections and lyophilized powder injections, 4 million oral solutions, suppositories, irons and other commonly used clinical dosage forms.
Staff size:300-399 persons

Registered capital:RMB 230 million

Producer:Guangxi Bangqi Pharmaceutical Co., Ltd. was established in 1996, with total assets of more than 800 million yuan and a total construction area of 81400 m2. The company has passed the new GMP certification of the State Drug Administration and has extensive influence in the national market. It is the largest decoct production base in the region.
Staff size:400-499 persons

Registered capital:RMB 133 million

Producer:Wuhan Wujing Pharmaceutical Co., Ltd. is a modern pharmaceutical enterprise focusing on the production of chemical raw materials and preparations for the use of facial features, covering an area of more than 100000 square meters and a construction area of about 30000 square meters. At present, there are 11 dosage forms: eye drops, nose drops, ear drops, solution, tincture, tablet, capsule, tablet, granule, liniment and API. The company passed GMP certification in 2003.
Staff size:200-299 persons

Registered capital:RMB 30 million